Skip to main content
Top
Published in: Breast Cancer Research 4/2005

Open Access 01-08-2005 | Research article

Designing a HER2/neupromoter to drive α1,3galactosyltransferase expression for targeted anti-αGal antibody-mediated tumor cell killing

Authors: Marion Lanteri, Laurence Ollier, Valérie Giordanengo, Jean-Claude Lefebvre

Published in: Breast Cancer Research | Issue 4/2005

Login to get access

Abstract

Introduction

Our goal was to specifically render tumor cells susceptible to natural cytolytic anti-αGal antibodies by using a murine α1,3galactosyltransferase (mαGalT) transgene driven by a designed form of HER2/neu promoter (pNeu), the transcription of which is frequently observed to be above basal in breast tumors. Indeed, the αGalT activity that promotes Galα1,3Galβ1,4GlcNAc-R (αGal) epitope expression has been mutationally disrupted during the course of evolution, starting from Old World primates, and this has led to the counter-production of large amounts of cytotoxic anti-αGal antibodies in recent primates, including man.

Method

Expression of the endogenous c-erbB-2 gene was investigated in various cell lines by northern blotting. A mαGalT cDNA was constructed into pcDNA3 vector downstream of the original CMV promoter (pCMV/mαGalT) and various forms of pNeu were prepared by PCR amplification and inserted in the pCMV/mαGalT construct upstream of the mαGalT cDNA, in the place of the CMV promoter. These constructs were transferred into HEK-293 control and breast tumor cell lines. Stably transfected cells were analyzed by northern blotting for their expression of αGalT and c-erbB-2, and by flow cytometry for their binding with fluorescein isothiocyanate-conjugated Griffonia simplicifolia/isolectin B4.

Results

We show that expression of the mαGalT was up- or down-modulated according to the level of endogenous pNeu activity and the particular form of constructed pNeu. Among several constructs, two particular forms of the promoter, pNeu250 containing the CCAAT box and the PEA3 motif adjacent to the TATAA box, and pNeu664, which has three additional PEA3 motifs upstream of the CCAAT box, were found to promote differential αGalT expression.

Conclusion

Our results strengthen current concepts about the crucial role played by the proximal PEA3 motif of pNeu, and may represent a novel therapeutic approach for the development of targeted transgene expression.
Appendix
Available only for authorised users
Literature
1.
go back to reference Galili U: Evolution of a 1,3Galactosyltransferase and of the a-Gal epitope. a-Gal and Anti-Gal: a-1,3-galactosyltransferase, a-Gal epitopes, and the natural anti-Gal antibody. Edited by: Galili U, Avila JL. 1999, New York, NY: Kluwer Academic/Plenum Publishers, 1-18.CrossRef Galili U: Evolution of a 1,3Galactosyltransferase and of the a-Gal epitope. a-Gal and Anti-Gal: a-1,3-galactosyltransferase, a-Gal epitopes, and the natural anti-Gal antibody. Edited by: Galili U, Avila JL. 1999, New York, NY: Kluwer Academic/Plenum Publishers, 1-18.CrossRef
2.
go back to reference Galili U, Shohet SB, Kobrin E, Stults CL, Macher BA: Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J Biol Chem. 1988, 263: 17755-17762.PubMed Galili U, Shohet SB, Kobrin E, Stults CL, Macher BA: Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J Biol Chem. 1988, 263: 17755-17762.PubMed
3.
go back to reference Lanteri M, Giordanengo V, Hiraoka N, Fuzibet JG, Auberger P, Fukuda M, Baum LG, Lefebvre JC: Altered T cell surface glycosylation in HIV type 1 infection results in increased susceptibility to galectin-1-induced cell death. Glycobiology. 2003, 13: 909-918. 10.1093/glycob/cwg110.CrossRefPubMed Lanteri M, Giordanengo V, Hiraoka N, Fuzibet JG, Auberger P, Fukuda M, Baum LG, Lefebvre JC: Altered T cell surface glycosylation in HIV type 1 infection results in increased susceptibility to galectin-1-induced cell death. Glycobiology. 2003, 13: 909-918. 10.1093/glycob/cwg110.CrossRefPubMed
4.
go back to reference Galili U, Avila JL: a-Gal and Anti-Gal: a-1,3-galactosyltransferase, a-Gal epitopes, and the natural anti-Gal antibody. 1999, New York, NY: Kluwer Academic/Plenum PublishersCrossRef Galili U, Avila JL: a-Gal and Anti-Gal: a-1,3-galactosyltransferase, a-Gal epitopes, and the natural anti-Gal antibody. 1999, New York, NY: Kluwer Academic/Plenum PublishersCrossRef
5.
go back to reference Hortobagyi GN, Hung MC, Lopez-Berestein G: A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer. Hum Gene Ther. 1998, 9: 1775-1798.CrossRefPubMed Hortobagyi GN, Hung MC, Lopez-Berestein G: A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer. Hum Gene Ther. 1998, 9: 1775-1798.CrossRefPubMed
6.
go back to reference Buhler L, Friedman T, Iacomini J, Cooper DK: Xenotransplantation – state of the art – update 1999. Front Biosci. 1999, 4: D416-432.CrossRefPubMed Buhler L, Friedman T, Iacomini J, Cooper DK: Xenotransplantation – state of the art – update 1999. Front Biosci. 1999, 4: D416-432.CrossRefPubMed
7.
go back to reference Jager U, Takeuchi Y, Porter CD: Sensitization of human cells to lysis by human complement as an approach for cancer gene therapy. Adv Exp Med Biol. 1998, 451: 359-363.CrossRefPubMed Jager U, Takeuchi Y, Porter CD: Sensitization of human cells to lysis by human complement as an approach for cancer gene therapy. Adv Exp Med Biol. 1998, 451: 359-363.CrossRefPubMed
8.
go back to reference Link CJ, Seregina T, Atchison R, Hall A, Muldoon R, Levy JP: Eliciting hyperacute xenograft response to treat human cancer: alpha(1,3) galactosyltransferase gene therapy. Anticancer Res. 1998, 18: 2301-2308.PubMed Link CJ, Seregina T, Atchison R, Hall A, Muldoon R, Levy JP: Eliciting hyperacute xenograft response to treat human cancer: alpha(1,3) galactosyltransferase gene therapy. Anticancer Res. 1998, 18: 2301-2308.PubMed
9.
go back to reference Unfer RC, Hellrung D, Link CJ: Immunity to the alpha(1,3)galactosyl epitope provides protection in mice challenged with colon cancer cells expressing alpha(1,3)galactosyl-transferase: a novel suicide gene for cancer gene therapy. Cancer Res. 2003, 63: 987-993.PubMed Unfer RC, Hellrung D, Link CJ: Immunity to the alpha(1,3)galactosyl epitope provides protection in mice challenged with colon cancer cells expressing alpha(1,3)galactosyl-transferase: a novel suicide gene for cancer gene therapy. Cancer Res. 2003, 63: 987-993.PubMed
10.
go back to reference Aubert M, Crotte C, Bernard JP, Lombardo D, Sadoulet MO, Mas E: Decrease of human pancreatic cancer cell tumorigenicity by alpha1,3galactosyltransferase gene transfer. Int J Cancer. 2003, 107: 910-918. 10.1002/ijc.11470.CrossRefPubMed Aubert M, Crotte C, Bernard JP, Lombardo D, Sadoulet MO, Mas E: Decrease of human pancreatic cancer cell tumorigenicity by alpha1,3galactosyltransferase gene transfer. Int J Cancer. 2003, 107: 910-918. 10.1002/ijc.11470.CrossRefPubMed
11.
go back to reference Dachs GU, Dougherty GJ, Stratford IJ, Chaplin DJ: Targeting gene therapy to cancer: a review. Oncol Res. 1997, 9: 313-325.PubMed Dachs GU, Dougherty GJ, Stratford IJ, Chaplin DJ: Targeting gene therapy to cancer: a review. Oncol Res. 1997, 9: 313-325.PubMed
12.
go back to reference Ring CJ, Blouin P, Martin LA, Hurst HC, Lemoine NR: Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes to drive tumour-selective expression of a prodrug activating enzyme. Gene Ther. 1997, 4: 1045-1052. 10.1038/sj.gt.3300510.CrossRefPubMed Ring CJ, Blouin P, Martin LA, Hurst HC, Lemoine NR: Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes to drive tumour-selective expression of a prodrug activating enzyme. Gene Ther. 1997, 4: 1045-1052. 10.1038/sj.gt.3300510.CrossRefPubMed
13.
go back to reference Manley PW, Martiny-Baron G, Schlaeppi JM, Wood JM: Therapies directed at vascular endothelial growth factor. Expert Opin Investig Drugs. 2002, 11: 1715-1736.CrossRefPubMed Manley PW, Martiny-Baron G, Schlaeppi JM, Wood JM: Therapies directed at vascular endothelial growth factor. Expert Opin Investig Drugs. 2002, 11: 1715-1736.CrossRefPubMed
14.
go back to reference Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987, 235: 177-182.CrossRefPubMed Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987, 235: 177-182.CrossRefPubMed
15.
go back to reference Kraus MH, Popescu NC, Amsbaugh SC, King CR: Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. Embo J. 1987, 6: 605-610.PubMedPubMedCentral Kraus MH, Popescu NC, Amsbaugh SC, King CR: Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. Embo J. 1987, 6: 605-610.PubMedPubMedCentral
16.
go back to reference Menard S, Pupa SM, Campiglio M, Tagliabue E: Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003, 22: 6570-6578. 10.1038/sj.onc.1206779.CrossRefPubMed Menard S, Pupa SM, Campiglio M, Tagliabue E: Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003, 22: 6570-6578. 10.1038/sj.onc.1206779.CrossRefPubMed
17.
go back to reference Brennan PJ, Kumagai T, Berezov A, Murali R, Greene MI, Kumogai T: HER2/neu: mechanisms of dimerization/oligomerization. Oncogene. 2000, 19: 6093-6101. 10.1038/sj.onc.1203967.CrossRefPubMed Brennan PJ, Kumagai T, Berezov A, Murali R, Greene MI, Kumogai T: HER2/neu: mechanisms of dimerization/oligomerization. Oncogene. 2000, 19: 6093-6101. 10.1038/sj.onc.1203967.CrossRefPubMed
18.
go back to reference Leone F, Perissinotto E, Cavalloni G, Fonsato V, Bruno S, Surrenti N, Hong D, Capaldi A, Geuna M, Piacibello W, et al: Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells. J Leukoc Biol. 2003, 74: 593-601. 10.1189/jlb.0203068.CrossRefPubMed Leone F, Perissinotto E, Cavalloni G, Fonsato V, Bruno S, Surrenti N, Hong D, Capaldi A, Geuna M, Piacibello W, et al: Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells. J Leukoc Biol. 2003, 74: 593-601. 10.1189/jlb.0203068.CrossRefPubMed
19.
go back to reference Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989, 244: 707-712.CrossRefPubMed Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989, 244: 707-712.CrossRefPubMed
20.
go back to reference Li BD, Harlow SP, Budnick RM, Sheedy DL, Stewart CC: Detection of HER-2/neu oncogene amplification in flow cytometry-sorted breast ductal cells by competitive polymerase chain reaction. Cancer. 1994, 73: 2771-2778.CrossRefPubMed Li BD, Harlow SP, Budnick RM, Sheedy DL, Stewart CC: Detection of HER-2/neu oncogene amplification in flow cytometry-sorted breast ductal cells by competitive polymerase chain reaction. Cancer. 1994, 73: 2771-2778.CrossRefPubMed
21.
go back to reference Lyon E, Millson A, Lowery MC, Woods R, Wittwer CT: Quantification of HER2/neu gene amplification by competitive pcr using fluorescent melting curve analysis. Clin Chem. 2001, 47: 844-851.PubMed Lyon E, Millson A, Lowery MC, Woods R, Wittwer CT: Quantification of HER2/neu gene amplification by competitive pcr using fluorescent melting curve analysis. Clin Chem. 2001, 47: 844-851.PubMed
22.
go back to reference Wang SC, Hung MC: Transcriptional targeting of the HER-2/neu oncogene. Drugs Today (Barc). 2000, 36: 835-843. Wang SC, Hung MC: Transcriptional targeting of the HER-2/neu oncogene. Drugs Today (Barc). 2000, 36: 835-843.
23.
go back to reference Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985, 230: 1132-1139.CrossRefPubMed Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985, 230: 1132-1139.CrossRefPubMed
24.
go back to reference Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, Yarden Y: The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA. 1999, 96: 4995-5000. 10.1073/pnas.96.9.4995.CrossRefPubMedPubMedCentral Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, Yarden Y: The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA. 1999, 96: 4995-5000. 10.1073/pnas.96.9.4995.CrossRefPubMedPubMedCentral
25.
go back to reference Holbro T, Civenni G, Hynes NE: The ErbB receptors and their role in cancer progression. Exp Cell Res. 2003, 284: 99-110. 10.1016/S0014-4827(02)00099-X.CrossRefPubMed Holbro T, Civenni G, Hynes NE: The ErbB receptors and their role in cancer progression. Exp Cell Res. 2003, 284: 99-110. 10.1016/S0014-4827(02)00099-X.CrossRefPubMed
26.
go back to reference Yu L, Kamo S, Tagawa M: Identification of a minimal c-erbB-2 promoter region that mediates preferential expression of a linked foreign gene in human breast cancer cells. Int J Oncol. 2002, 20: 607-610.PubMed Yu L, Kamo S, Tagawa M: Identification of a minimal c-erbB-2 promoter region that mediates preferential expression of a linked foreign gene in human breast cancer cells. Int J Oncol. 2002, 20: 607-610.PubMed
27.
go back to reference Yu SF, von Ruden T, Kantoff PW, Garber C, Seiberg M, Ruther U, Anderson WF, Wagner EF, Gilboa E: Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA. 1986, 83: 3194-3198.CrossRefPubMedPubMedCentral Yu SF, von Ruden T, Kantoff PW, Garber C, Seiberg M, Ruther U, Anderson WF, Wagner EF, Gilboa E: Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA. 1986, 83: 3194-3198.CrossRefPubMedPubMedCentral
28.
go back to reference Lefebvre JC, Giordanengo V, Limouse M, Doglio A, Cucchiarini M, Monpoux F, Mariani R, Peyron JF: Altered glycosylation of leukosialin, CD43, in HIV-1-infected cells of the CEM line. J Exp Med. 1994, 180: 1609-1617. 10.1084/jem.180.5.1609.CrossRefPubMed Lefebvre JC, Giordanengo V, Limouse M, Doglio A, Cucchiarini M, Monpoux F, Mariani R, Peyron JF: Altered glycosylation of leukosialin, CD43, in HIV-1-infected cells of the CEM line. J Exp Med. 1994, 180: 1609-1617. 10.1084/jem.180.5.1609.CrossRefPubMed
29.
go back to reference Giordanengo V, Bannwarth S, Laffont C, Van-Miegem V, Harduin-Lepers A, Delannoy P, Lefebvre JC: Cloning and expression of cDNA for a human Gal(b1-3)GalNAc a2,3-sialyltransferase from the CEM-T cell line. Eur J Biochem. 1997, 247: 558-566. 10.1111/j.1432-1033.1997.00558.x.CrossRefPubMed Giordanengo V, Bannwarth S, Laffont C, Van-Miegem V, Harduin-Lepers A, Delannoy P, Lefebvre JC: Cloning and expression of cDNA for a human Gal(b1-3)GalNAc a2,3-sialyltransferase from the CEM-T cell line. Eur J Biochem. 1997, 247: 558-566. 10.1111/j.1432-1033.1997.00558.x.CrossRefPubMed
30.
go back to reference Wright M, Grim J, Deshane J, Kim M, Strong TV, Siegal GP, Curiel DT: An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2. Gene Ther. 1997, 4: 317-322. 10.1038/sj.gt.3300372.CrossRefPubMed Wright M, Grim J, Deshane J, Kim M, Strong TV, Siegal GP, Curiel DT: An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2. Gene Ther. 1997, 4: 317-322. 10.1038/sj.gt.3300372.CrossRefPubMed
31.
go back to reference Brodowicz T, Wiltschke C, Budinsky AC, Krainer M, Steger GG, Zielinski CC: Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. Int J Cancer. 1997, 73: 875-879. 10.1002/(SICI)1097-0215(19971210)73:6<875::AID-IJC19>3.0.CO;2-3.CrossRefPubMed Brodowicz T, Wiltschke C, Budinsky AC, Krainer M, Steger GG, Zielinski CC: Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. Int J Cancer. 1997, 73: 875-879. 10.1002/(SICI)1097-0215(19971210)73:6<875::AID-IJC19>3.0.CO;2-3.CrossRefPubMed
32.
go back to reference Kumar R, Mandal M, Lipton A, Harvey H, Thompson CB: Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin Cancer Res. 1996, 2: 1215-1219.PubMed Kumar R, Mandal M, Lipton A, Harvey H, Thompson CB: Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin Cancer Res. 1996, 2: 1215-1219.PubMed
33.
go back to reference Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL: Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 2000, 60: 5887-5894.PubMed Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL: Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 2000, 60: 5887-5894.PubMed
34.
go back to reference Child SJ, Miller MK, Geballe AP: Cell type-dependent and -independent control of HER-2/neu translation. Int J Biochem Cell Biol. 1999, 31: 201-213. 10.1016/S1357-2725(98)00068-5.CrossRefPubMed Child SJ, Miller MK, Geballe AP: Cell type-dependent and -independent control of HER-2/neu translation. Int J Biochem Cell Biol. 1999, 31: 201-213. 10.1016/S1357-2725(98)00068-5.CrossRefPubMed
35.
go back to reference Graham FL, Smiley J, Russell WC, Nairn R: Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977, 36: 59-74.CrossRefPubMed Graham FL, Smiley J, Russell WC, Nairn R: Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977, 36: 59-74.CrossRefPubMed
36.
go back to reference Quinlan MP: Expression of antisense E1A in 293 cells results in altered cell morphologies and cessation of proliferation. Oncogene. 1993, 8: 257-265.PubMed Quinlan MP: Expression of antisense E1A in 293 cells results in altered cell morphologies and cessation of proliferation. Oncogene. 1993, 8: 257-265.PubMed
37.
go back to reference Kamei D, Murakami M, Nakatani Y, Ishikawa Y, Ishii T, Kudo I: Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J Biol Chem. 2003, 278: 19396-19405. 10.1074/jbc.M213290200.CrossRefPubMed Kamei D, Murakami M, Nakatani Y, Ishikawa Y, Ishii T, Kudo I: Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J Biol Chem. 2003, 278: 19396-19405. 10.1074/jbc.M213290200.CrossRefPubMed
39.
go back to reference Galili U, Rachmilewitz EA, Peleg A, Flechner I: A unique natural human IgG antibody with anti-alpha-galactosyl specificity. J Exp Med. 1984, 160: 1519-1531. 10.1084/jem.160.5.1519.CrossRefPubMed Galili U, Rachmilewitz EA, Peleg A, Flechner I: A unique natural human IgG antibody with anti-alpha-galactosyl specificity. J Exp Med. 1984, 160: 1519-1531. 10.1084/jem.160.5.1519.CrossRefPubMed
40.
go back to reference Good AH, Cooper DK, Malcolm AJ, Ippolito RM, Koren E, Neethling FA, Ye Y, Zuhdi N, Lamontagne LR: Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans. Transplant Proc. 1992, 24: 559-562.PubMed Good AH, Cooper DK, Malcolm AJ, Ippolito RM, Koren E, Neethling FA, Ye Y, Zuhdi N, Lamontagne LR: Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans. Transplant Proc. 1992, 24: 559-562.PubMed
41.
go back to reference Thall AD, Murphy HS, Lowe JB: alpha 1,3-Galactosyltransferase-deficient mice produce naturally occurring cytotoxic anti-Gal antibodies. Transplant Proc. 1996, 28: 556-557.PubMed Thall AD, Murphy HS, Lowe JB: alpha 1,3-Galactosyltransferase-deficient mice produce naturally occurring cytotoxic anti-Gal antibodies. Transplant Proc. 1996, 28: 556-557.PubMed
42.
go back to reference Salvaris E, Gock H, Han W, Murray-Segal L, Barlow H, Mottram P, Pearse M, Cowan P, Goodman D, d'Apice AJ: Naturally acquired anti-alpha Gal antibodies in a murine allograft model similar to delayed xenograft rejection. Xenotransplantation. 2000, 7: 42-47. 10.1034/j.1399-3089.2000.00040.x.CrossRefPubMed Salvaris E, Gock H, Han W, Murray-Segal L, Barlow H, Mottram P, Pearse M, Cowan P, Goodman D, d'Apice AJ: Naturally acquired anti-alpha Gal antibodies in a murine allograft model similar to delayed xenograft rejection. Xenotransplantation. 2000, 7: 42-47. 10.1034/j.1399-3089.2000.00040.x.CrossRefPubMed
43.
go back to reference Sawada T, Yamada O, Yoshimura N, Hatori K, Fuchinoue S, Teraoka S: Xenoantigen, an alphaGal epitope-expression construct driven by the hTERT-promoter, specifically kills human pancreatic cancer cell line. Cancer Cell Int. 2002, 2: 14-20. 10.1186/1475-2867-2-14.CrossRefPubMedPubMedCentral Sawada T, Yamada O, Yoshimura N, Hatori K, Fuchinoue S, Teraoka S: Xenoantigen, an alphaGal epitope-expression construct driven by the hTERT-promoter, specifically kills human pancreatic cancer cell line. Cancer Cell Int. 2002, 2: 14-20. 10.1186/1475-2867-2-14.CrossRefPubMedPubMedCentral
44.
go back to reference Arteaga CL, Chinratanalab W, Carter MB: Inhibitors of HER2/neu (erbB-2) signal transduction. Semin Oncol. 2001, 28: 30-35. 10.1053/sonc.2001.29722.CrossRefPubMed Arteaga CL, Chinratanalab W, Carter MB: Inhibitors of HER2/neu (erbB-2) signal transduction. Semin Oncol. 2001, 28: 30-35. 10.1053/sonc.2001.29722.CrossRefPubMed
45.
go back to reference Hurst HC: Update on HER-2 as a target for cancer therapy: the ERBB2 promoter and its exploitation for cancer treatment. Breast Cancer Res. 2001, 3: 395-398. 10.1186/bcr329.CrossRefPubMedPubMedCentral Hurst HC: Update on HER-2 as a target for cancer therapy: the ERBB2 promoter and its exploitation for cancer treatment. Breast Cancer Res. 2001, 3: 395-398. 10.1186/bcr329.CrossRefPubMedPubMedCentral
46.
go back to reference Scott GK, Chang CH, Erny KM, Xu F, Fredericks WJ, Rauscher FJ, Thor AD, Benz CC: Ets regulation of the erbB2 promoter. Oncogene. 2000, 19: 6490-6502. 10.1038/sj.onc.1204041.CrossRefPubMed Scott GK, Chang CH, Erny KM, Xu F, Fredericks WJ, Rauscher FJ, Thor AD, Benz CC: Ets regulation of the erbB2 promoter. Oncogene. 2000, 19: 6490-6502. 10.1038/sj.onc.1204041.CrossRefPubMed
47.
go back to reference Xing X, Wang SC, Xia W, Zou Y, Shao R, Kwong KY, Yu Z, Zhang S, Miller S, Huang L, et al: The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat Med. 2000, 6: 189-195. 10.1038/72294.CrossRefPubMed Xing X, Wang SC, Xia W, Zou Y, Shao R, Kwong KY, Yu Z, Zhang S, Miller S, Huang L, et al: The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat Med. 2000, 6: 189-195. 10.1038/72294.CrossRefPubMed
48.
go back to reference Yu D, Suen TC, Yan DH, Chang LS, Hung MC: Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci USA. 1990, 87: 4499-4503.CrossRefPubMedPubMedCentral Yu D, Suen TC, Yan DH, Chang LS, Hung MC: Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci USA. 1990, 87: 4499-4503.CrossRefPubMedPubMedCentral
49.
go back to reference Chang JY, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung MC: The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene. 1997, 14: 561-568. 10.1038/sj.onc.1200861.CrossRefPubMed Chang JY, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung MC: The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene. 1997, 14: 561-568. 10.1038/sj.onc.1200861.CrossRefPubMed
50.
go back to reference Yu D, Hung MC: Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. 2000, 19: 6115-6121. 10.1038/sj.onc.1203972.CrossRefPubMed Yu D, Hung MC: Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. 2000, 19: 6115-6121. 10.1038/sj.onc.1203972.CrossRefPubMed
51.
go back to reference Beckhove P, Schutz F, Diel IJ, Solomayer EF, Bastert G, Foerster J, Feuerer M, Bai L, Sinn HP, Umansky V, et al: Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice. Int J Cancer. 2003, 105: 444-453. 10.1002/ijc.11125.CrossRefPubMed Beckhove P, Schutz F, Diel IJ, Solomayer EF, Bastert G, Foerster J, Feuerer M, Bai L, Sinn HP, Umansky V, et al: Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice. Int J Cancer. 2003, 105: 444-453. 10.1002/ijc.11125.CrossRefPubMed
52.
go back to reference Thall AD, Maly P, Lowe JB: Oocyte Gal alpha 1,3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse. J Biol Chem. 1995, 270: 21437-21440. 10.1074/jbc.270.37.21437.CrossRefPubMed Thall AD, Maly P, Lowe JB: Oocyte Gal alpha 1,3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse. J Biol Chem. 1995, 270: 21437-21440. 10.1074/jbc.270.37.21437.CrossRefPubMed
53.
go back to reference Tearle RG, Tange MJ, Zannettino ZL, Katerelos M, Shinkel TA, Van Denderen BJ, Lonie AJ, Lyons I, Nottle MB, Cox T, et al: The alpha-1,3-galactosyltransferase knockout mouse. Implications for xenotransplantation. Transplantation. 1996, 61: 13-19. 10.1097/00007890-199601150-00004.CrossRefPubMed Tearle RG, Tange MJ, Zannettino ZL, Katerelos M, Shinkel TA, Van Denderen BJ, Lonie AJ, Lyons I, Nottle MB, Cox T, et al: The alpha-1,3-galactosyltransferase knockout mouse. Implications for xenotransplantation. Transplantation. 1996, 61: 13-19. 10.1097/00007890-199601150-00004.CrossRefPubMed
Metadata
Title
Designing a HER2/neupromoter to drive α1,3galactosyltransferase expression for targeted anti-αGal antibody-mediated tumor cell killing
Authors
Marion Lanteri
Laurence Ollier
Valérie Giordanengo
Jean-Claude Lefebvre
Publication date
01-08-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 4/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1034

Other articles of this Issue 4/2005

Breast Cancer Research 4/2005 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine